A new study from the University of Manchester has revealed that every year, thousands of people with mental health conditions in the UK are missing out on cutting-edge treatments because the NHS is losing ground to private companies in clinical research
Over the past five years, NHS recruitment into commercial clinical trials has collapsed by 44%. In that time, private contract research organisations (CROs) have surged ahead, offering dedicated facilities, slicker operations, and higher payments to participants. Pharmaceutical companies are now choosing these private firms over the NHS and universities to run early-stage mental health trials.
The study, published in the journal Brain, asked both pharmaceutical executives and patients who had taken part in mental health trials for their views.
Patients said they were driven to take part by the chance of closer medical monitoring, early access to promising new medicines, and the hope of improving services for others. But many reported frustrations with NHS-led studies – including lack of communication, no updates after the trial ended, and confusion over how their data was used.
Crucially, money makes a difference. CROs typically offer far more generous reimbursements than the NHS, making trial participation more appealing. The researchers argue that if the NHS is serious about competing, it must review how it compensates patients.
“The NHS has world-class expertise and access to diverse patient groups, but without new investment and streamlined systems, we risk missing out on breakthroughs in mental health treatments,” said Dr Aiste Adomaviciene, lead researcher from Manchester’s Division of Psychology and Mental Health.
